Genitourinary Cancer

This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Genitourinary Pathology.

By MCL Education • April 9, 2021

Dr. Pandey is a nuclear radiology researcher working with a team to develop a new radioactive tracer to detect prostate cancer.

By Suzanne Ferguson • September 5, 2019

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.

By Mayo Clinic News Network • January 15, 2019

This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.

By Kelley Luedke • May 21, 2018

This week’s Research Roundup highlights how the loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion.

By Kelley Luedke • January 15, 2018

This week’s Research Roundup highlights individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.

By Kelley Luedke • September 4, 2017

This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

By Kelley Luedke • August 21, 2017

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

By Alicia Algeciras-Schimnich, Ph.D. • August 14, 2017

The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.

By Gina Chiri-Osmond • July 28, 2017

This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.

By Kelley Luedke • May 15, 2017
Video Overview Clinical Information Specimen Performance

Useful For
  • Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL.
  • Results from a prospective, multicenter clinical trial found that phi provides better risk stratification and [...]
By Mayo Clinic Laboratories • May 9, 2017